Potential prognostic and predictive factors in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) in daily clinical practice in Spain.
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record